Messmore HL - Search Results

1

Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia.

Walenga JM, Jeske WP, Messmore HL. Walenga JM, et al. Among authors: messmore hl. J Thromb Thrombolysis. 2000 Nov;10 Suppl 1:13-20. doi: 10.1023/a:1027372901367. J Thromb Thrombolysis. 2000. PMID: 11155190 Review.

2

Benefit-risk assessment of treatments for heparin-induced thrombocytopenia.

Messmore H, Jeske W, Wehrmacher W, Walenga J. Messmore H, et al. Drug Saf. 2003;26(9):625-41. doi: 10.2165/00002018-200326090-00003. Drug Saf. 2003. PMID: 12814331 Review.

3

Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG.

Untch B, Ahmad S, Jeske WP, Messmore HL, Hoppensteadt DA, Walenga JM, Lietz H, Fareed J. Untch B, et al. Among authors: messmore hl. Thromb Res. 2002 Jan 15;105(2):117-23. doi: 10.1016/s0049-3848(02)00004-x. Thromb Res. 2002. PMID: 11958801

4

Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.

Untch B, Ahmad S, Messmore HL, Schultz CL, Ma Q, Hoppensteadt DA, Walenga JM, Fareed J. Untch B, et al. Among authors: messmore hl. Thromb Res. 2002 Apr 15;106(2):149-56. doi: 10.1016/s0049-3848(02)00081-6. Thromb Res. 2002. PMID: 12182915

5

Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.

Ahmad S, Haas S, Hoppensteadt DA, Lietz H, Reid U, Bender N, Messmore HL, Misselwitz F, Bacher P, Gaikwad BS, Jeske WP, Walenga JM, Fareed J. Ahmad S, et al. Among authors: messmore hl. Thromb Res. 2002 Oct 1;108(1):49-55. doi: 10.1016/s0049-3848(02)00397-3. Thromb Res. 2002. PMID: 12586132 Clinical Trial.

6

Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis.

Ahmad S, Untch B, Haas S, Hoppensteadt DA, Misselwitz F, Messmore HL, Walenga JM, Fareed J. Ahmad S, et al. Among authors: messmore hl. Mol Cell Biochem. 2004 Mar;258(1-2):163-70. doi: 10.1023/b:mcbi.0000012852.60500.30. Mol Cell Biochem. 2004. PMID: 15030181

7

Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.

Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M. Walenga JM, et al. Among authors: messmore hl. Br J Haematol. 2008 Oct;143(1):92-9. doi: 10.1111/j.1365-2141.2008.07300.x. Epub 2008 Jul 30. Br J Haematol. 2008. PMID: 18671707 Free article.

8

Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog.

Chamberlin JR, Lewis B, Leya F, Wallis D, Messmore H, Hoppensteadt D, Walenga JM, Moran S, Fareed J, McKiernan T. Chamberlin JR, et al. Can J Cardiol. 1995 Jun;11(6):511-4. Can J Cardiol. 1995. PMID: 7780873

9

Evaluation of a low molecular weight heparin as an anticoagulant in a model of cardiopulmonary bypass surgery.

Koza MJ, Messmore HL, Wallock ME, Walenga JM, Pifarre R. Koza MJ, et al. Among authors: messmore hl. Thromb Res. 1993 Apr 1;70(1):67-76. doi: 10.1016/0049-3848(93)90224-c. Thromb Res. 1993. PMID: 8390111

10

Ethylenediaminetetraacetic acid (EDTA) in heparin.

Coyne E, Messmore HL, Walenga JM, Fareed J, Wehrmacher WH. Coyne E, et al. Among authors: messmore hl. Thromb Res. 1998 Jun 1;90(5):245-6. doi: 10.1016/s0049-3848(98)00063-2. Thromb Res. 1998. PMID: 9694247 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

125 results

Search Page

Filters